Dorrington Medical Associates , 2219 Dorrington Street, Houston, Texas 77030 , USA.
Expert Opin Pharmacother. 2012 Feb;13(3):387-93. doi: 10.1517/14656566.2012.651126. Epub 2012 Jan 18.
Clevidipine butyrate is the first intravenous antihypertensive drug to be approved by the FDA over the last decade. This medication is approved for use in the USA, Australia and New Zealand, but is still pending for approval in Europe. It is a new agent that might change the current management for severe acute hypertension in the critical care, emergency and perioperative areas.
This systematic review summarizes the pharmacological and clinical characteristics of this third-generation dihydropyridine intravenous calcium channel blocker, and was done using the literature available from the first publication in 1999 up until now, including the pivotal trials that led to its approval.
This agent is arterially selective, has an ultrashort half-life, with no CYP-mediated interactions with other medications and is easily titratable. These characteristics place it in a unique category compared with other commonly used antihypertensives. Clevidipine butyrate reaches target systolic blood pressure in more than 90% of patients, within 30 min. It has a low incidence of adverse reactions and is generally well tolerated. The main goal of this review is to provide healthcare providers with a comprehensive appraisal of this promising medication.
丁酸己脂拉贝洛尔是过去十年间首个获得美国 FDA 批准的静脉内抗高血压药物。该药已在美国、澳大利亚和新西兰获得批准使用，但在欧洲仍有待批准。它是一种新的药物，可能会改变目前在重症监护、急救和围手术期领域严重急性高血压的治疗方法。
本系统评价总结了第三代二氢吡啶类静脉内钙通道阻滞剂的药理学和临床特征，使用的文献资料最早可追溯至 1999 年首次发表的内容，包括导致其获得批准的关键性试验。
该药物具有动脉选择性，半衰期极短，与其他药物无 CYP 介导的相互作用，且易于滴定。与其他常用的降压药相比，这些特性使它具有独特的地位。丁酸己脂拉贝洛尔在 30 分钟内使超过 90%的患者达到目标收缩压。不良反应发生率低，一般耐受性良好。本综述的主要目的是为医疗保健提供者提供对这种有前途的药物的全面评估。
